This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy (PVA) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy (PVA) Treatment. This report contains market size and forecasts of Postmenopausal Vaginal Atrophy (PVA) Treatment in global, including the following market information:
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Postmenopausal Vaginal Atrophy (PVA) Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Systemic Estrogen Treatments Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Postmenopausal Vaginal Atrophy (PVA) Treatment include EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD, Bionovo, Pfizer, Novo Nordisk, Allergan, Shionogi and Ligand Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Postmenopausal Vaginal Atrophy (PVA) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, by Type, 2022 (%)
Systemic Estrogen Treatments
Non-estrogenic Therapies
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinics
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Postmenopausal Vaginal Atrophy (PVA) Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Postmenopausal Vaginal Atrophy (PVA) Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
EndoCeutics
Upsher-Smith Laboratories
TherapeuticsMD
Bionovo
Pfizer
Novo Nordisk
Allergan
Shionogi
Ligand Pharmaceuticals
Bayer
Pantarhei Bioscience
Foamix Pharmaceuticals
Pep-Tonic Medical
Teva Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Postmenopausal Vaginal Atrophy (PVA) Treatment, market overview.
Chapter 2: Global Postmenopausal Vaginal Atrophy (PVA) Treatment market size in revenue.
Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Postmenopausal Vaginal Atrophy (PVA) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Overall Market Size
2.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size: 2022 VS 2032
2.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market
3.2 Top Global Postmenopausal Vaginal Atrophy (PVA) Treatment Companies Ranked by Revenue
3.3 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Postmenopausal Vaginal Atrophy (PVA) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Markets, 2022 & 2032
4.1.2 Systemic Estrogen Treatments
4.1.3 Non-estrogenic Therapies
4.2 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts
4.2.1 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2023
4.2.2 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2024-2032
4.2.3 By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2022 & 2032
5.1.2 Hospital
5.1.3 Clinics
5.2 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts
5.2.1 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2023
5.2.2 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2024-2032
5.2.3 By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2022 & 2032
6.2 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue & Forecasts
6.2.1 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2023
6.2.2 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2024-2032
6.2.3 By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032
6.3.2 US Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.3.3 Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.3.4 Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032
6.4.2 Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.3 France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.4 U.K. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.5 Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.6 Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.7 Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.4.8 Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032
6.5.2 China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.5.3 Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.5.4 South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.5.5 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.5.6 India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032
6.6.2 Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.6.3 Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032
6.7.2 Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.7.3 Israel Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.7.4 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
6.7.5 UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, 2018-2032
7 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies Profiles
7.1 EndoCeutics
7.1.1 EndoCeutics Company Summary
7.1.2 EndoCeutics Business Overview
7.1.3 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.1.4 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.1.5 EndoCeutics Key News & Latest Developments
7.2 Upsher-Smith Laboratories
7.2.1 Upsher-Smith Laboratories Company Summary
7.2.2 Upsher-Smith Laboratories Business Overview
7.2.3 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.2.4 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.2.5 Upsher-Smith Laboratories Key News & Latest Developments
7.3 TherapeuticsMD
7.3.1 TherapeuticsMD Company Summary
7.3.2 TherapeuticsMD Business Overview
7.3.3 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.3.4 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.3.5 TherapeuticsMD Key News & Latest Developments
7.4 Bionovo
7.4.1 Bionovo Company Summary
7.4.2 Bionovo Business Overview
7.4.3 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.4.4 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.4.5 Bionovo Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.5.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Novo Nordisk
7.6.1 Novo Nordisk Company Summary
7.6.2 Novo Nordisk Business Overview
7.6.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.6.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.6.5 Novo Nordisk Key News & Latest Developments
7.7 Allergan
7.7.1 Allergan Company Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.7.4 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.7.5 Allergan Key News & Latest Developments
7.8 Shionogi
7.8.1 Shionogi Company Summary
7.8.2 Shionogi Business Overview
7.8.3 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.8.4 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.8.5 Shionogi Key News & Latest Developments
7.9 Ligand Pharmaceuticals
7.9.1 Ligand Pharmaceuticals Company Summary
7.9.2 Ligand Pharmaceuticals Business Overview
7.9.3 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.9.4 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.9.5 Ligand Pharmaceuticals Key News & Latest Developments
7.10 Bayer
7.10.1 Bayer Company Summary
7.10.2 Bayer Business Overview
7.10.3 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.10.4 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.10.5 Bayer Key News & Latest Developments
7.11 Pantarhei Bioscience
7.11.1 Pantarhei Bioscience Company Summary
7.11.2 Pantarhei Bioscience Business Overview
7.11.3 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.11.4 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.11.5 Pantarhei Bioscience Key News & Latest Developments
7.12 Foamix Pharmaceuticals
7.12.1 Foamix Pharmaceuticals Company Summary
7.12.2 Foamix Pharmaceuticals Business Overview
7.12.3 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.12.4 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.12.5 Foamix Pharmaceuticals Key News & Latest Developments
7.13 Pep-Tonic Medical
7.13.1 Pep-Tonic Medical Company Summary
7.13.2 Pep-Tonic Medical Business Overview
7.13.3 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.13.4 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.13.5 Pep-Tonic Medical Key News & Latest Developments
7.14 Teva Pharmaceuticals
7.14.1 Teva Pharmaceuticals Company Summary
7.14.2 Teva Pharmaceuticals Business Overview
7.14.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Major Product Offerings
7.14.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global Market (2018-2023)
7.14.5 Teva Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Opportunities & Trends in Global Market
Table 2. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers in Global Market
Table 3. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints in Global Market
Table 4. Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment in Global Market
Table 5. Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Postmenopausal Vaginal Atrophy (PVA) Treatment Product Type
Table 9. List of Global Tier 1 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy (PVA) Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2024-2032
Table 30. EndoCeutics Company Summary
Table 31. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 32. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. EndoCeutics Key News & Latest Developments
Table 34. Upsher-Smith Laboratories Company Summary
Table 35. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 36. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Upsher-Smith Laboratories Key News & Latest Developments
Table 38. TherapeuticsMD Company Summary
Table 39. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 40. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. TherapeuticsMD Key News & Latest Developments
Table 42. Bionovo Company Summary
Table 43. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 44. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Bionovo Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 48. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Novo Nordisk Company Summary
Table 51. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 52. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Novo Nordisk Key News & Latest Developments
Table 54. Allergan Company Summary
Table 55. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 56. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Allergan Key News & Latest Developments
Table 58. Shionogi Company Summary
Table 59. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 60. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Shionogi Key News & Latest Developments
Table 62. Ligand Pharmaceuticals Company Summary
Table 63. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 64. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Ligand Pharmaceuticals Key News & Latest Developments
Table 66. Bayer Company Summary
Table 67. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 68. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Bayer Key News & Latest Developments
Table 70. Pantarhei Bioscience Company Summary
Table 71. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 72. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. Pantarhei Bioscience Key News & Latest Developments
Table 74. Foamix Pharmaceuticals Company Summary
Table 75. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 76. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 77. Foamix Pharmaceuticals Key News & Latest Developments
Table 78. Pep-Tonic Medical Company Summary
Table 79. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 80. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 81. Pep-Tonic Medical Key News & Latest Developments
Table 82. Teva Pharmaceuticals Company Summary
Table 83. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product Offerings
Table 84. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (US$, Mn) & (2018-2023)
Table 85. Teva Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Segment by Type in 2022
Figure 2. Postmenopausal Vaginal Atrophy (PVA) Treatment Segment by Application in 2022
Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in 2022
Figure 8. By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 9. By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 10. By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 12. By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 14. By Region - Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 15. By Country - North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 16. US Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 20. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 21. France Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 28. China Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 32. India Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 34. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share, 2018-2032
Figure 37. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, (US$, Mn), 2018-2032
Figure 41. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
